https://biospectrumindia.com/rssfeed/bio-interactions/industry%20report industry report https://biospectrumindia.com/news/34/25319/cphi-pmec-india-2024-poised-for-record-breaking-attendance-with-50000-pharma-executives.html https://biospectrumindia.com/news/34/25319/cphi-pmec-india-2024-poised-for-record-breaking-attendance-with-50000-pharma-executives.html Mon, 04 Nov 2024 00:00:00 +0530 CPHI & PMEC India (26th- 28th November, 2024) – the largest pharma event in India  –  returns next month, with a record attendance of over 50,000 pharma executives expected from more than 150 countries.   The news is a further boon for India – widely identified by analysts as a key beneficiary of recent macro tensions – as a strong CPHI & PMEC India is a leading indicator of growth for the country in the year ahead. In fact, emphasizing this shift in prospects, this year’s event will be the largest ever, with more than 2,000 exhibitors (hundreds more than previous editions).   Supporting India’s growth trajectory, the newly released CPHI Annual Survey 2024 once again ranks India as the top ‘growth nation’ for the upcoming 12 months, solidifying its lead over other major pharma hubs. This growth is driven by positive developments in the CDMO sector and an anticipated surge in CRO services accelerated by initiatives like BIOSECURE. Mirroring this trend, India also topped the CDMO table for predicted ‘growth over the next three years’ and finished only narrowly behind  the USA  for ‘overall competitiveness.   Olga Ponomareva-Stepnaya, Brand Manager of CPHI & PMEC India, commented: “It has been an incredibly positive year for the Indian pharma industry, and we are witnessing this firsthand with a record attendance, including over 5,000 international participants. On the show floor we are seeing a wide breadth of local ingredient suppliers, alongside many new advanced equipment providers as the country and regional partners seek to wider their supplier base and modernize equipment during this period of growth.”   CPHI India has responded to rising demand by launching several new initiatives, including the Connections Programme, offering a dedicated service for attendees seeking high-value deals. The programme is designed to help connect international key buyers with the right exhibitors and make high-value deals following feedback was challenging to meet the right supplier at such a large event.’   Reflecting wider industry trends, the event has also seen increased interest in start-up companies and will host a dedicated space for emerging enterprises disrupting the pharmaceutical landscape in India. The campaign forms part of Informa’s wider commitment to innovation with similar start-up programmes launched at other global CPHI events.   To help attendees capitalize on growth opportunities, the event’s conference agenda will feature xx sessions covering spanning two separate streams: the day one ‘Pharma Manufacturing Conclave’ and the day two ‘Pharma Sustainability Conclave’. Topics include key issues from biosimilar supply chains, manufacturing infrastructure for next-gen therapeutics, to addressing critical sustainability challenges in Indian pharma and new approach to green chemistry and pharm regulations.   The India Pharma Awards 2024, now in its 11th edition, will recognize excellence across 13 categories, celebrating the contributions of industry leaders, innovators, and visionaries from across the Indian pharmaceutical sector. The awards ceremony will take place on the evening of 28th November 2024 at the Expo Centre.   ]]> https://biospectrumindia.com/reports-white-papers/34/13948/biospectrum-india-a-leading-b2b-media-platform-in-life-sciences-and-bio-sciences-space-has-announced-its-15th-biospectrum-biopharma-survey-results-.html https://biospectrumindia.com/reports-white-papers/34/13948/biospectrum-india-a-leading-b2b-media-platform-in-life-sciences-and-bio-sciences-space-has-announced-its-15th-biospectrum-biopharma-survey-results-.html Thu, 20 Jun 2019 09:00:00 +0530 Highlights of the survey include For the year 2018-19 the Indian Biopharma Industry crossed Rs 22,124 crore over previous year's revenue of Rs 18,290 core. The Indian Biopharma Industry has exported products worth Rs 14,423 crore in 2018-19 witnessing growth over last year's exports of 13,925 crore. Indian Biopharma industry, comprising hormones, insulin, blood products and vaccines also imported biopharma products worth Rs 5500 core in 2018-19 as against previous year's imports of Rs 5039 crore. Serum Institute of India Ltd retains No 1 position Serum Institute of India Ltd (Pune) continues to lead the India biopharmaceutical industry with revenue of Rs 4984 crore followed by Biocon (Bangalore) (Rs 3946 crore) and Novo Nordisk (Bangalore) with Rs 1352 crore. Top 20 biopharma companies contribute to 89% of the total biopharma industry Indian companies contribute 78% of the total biopharma industry while remaining 22% by the MNC firms Western region continues to dominate the biopharma industry with contribution of 59% followed by Southern region with 36% and remaining 4% coming from Northern region. Serum Institute of India Ltd, (Pune), Glaxosmithkline Pharmaceuticals Ltd. (Mumbai), Sanofi India Ltd. (Mumbai), Reliance Life Science Pvt Ltd (Mumbai), and Intas Pharmaceuticals Ltd (Ahmedabad) are the top 5 companies from Western region. Biocon Ltd (Bangalore), Novo Nordisk India Pvt Ltd, (Bangalore), Bharat Biotech International Ltd (Hyderabad), Biological E Ltd (Hyderabad), and Indian Immunologicals Ltd (Hyderabad), are the 5 companies from Southern region. Baxter India (Gurugram), Panacea Biotec (New Delhi), Eli Lilly and Company (India) (Gurugram), Bharat Immunologicals and Biologicals Corporation Ltd (Bulandshahr) and Mankind Pharmaceuticals (New Delhi) are the top 5 companies from the Northern region. Click here to access BioSpectrum Top 20 Biopharma Companies ]]>